S&P 500
(-0.06%) 5 184.51 points
Dow Jones
(0.35%) 39 021 points
Nasdaq
(-0.24%) 16 293 points
Oil
(0.87%) $79.06
Gas
(-1.18%) $2.18
Gold
(-0.15%) $2 320.60
Silver
(0.23%) $27.61
Platinum
(-0.23%) $986.15
USD/EUR
(0.10%) $0.930
USD/NOK
(0.03%) $10.90
USD/GBP
(0.10%) $0.800
USD/RUB
(0.20%) $91.63

Actualizaciones en tiempo real para Celldex Therapeutics Inc [CLDX]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
BUY
75.00%
return -0.54%
SELL
40.00%
return 3.59%
Última actualización8 may 2024 @ 14:58

-2.72% $ 41.06

COMPRAR 120969 min ago

@ $36.11

Emitido: 14 feb 2024 @ 13:49


Retorno: 13.72%


Señal anterior: feb 13 - 12:40


Señal anterior: Vender


Retorno: 0.46 %

Live Chart Being Loaded With Signals

Commentary (8 may 2024 @ 14:58):
Profile picture for Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases...

Stats
Volumen de hoy 187 525
Volumen promedio 939 698
Capitalización de mercado 2.71B
EPS $0 ( 2024-05-02 )
Próxima fecha de ganancias ( $-0.690 ) 2024-06-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -14.36
ATR14 $0.0480 (0.12%)
Insider Trading
Date Person Action Amount type
2024-02-13 Jimenez Freddy A. Buy 20 000 Common Stock
2024-02-13 Jimenez Freddy A. Buy 4 166 Common Stock
2024-02-13 Jimenez Freddy A. Sell 4 166 Incentive Stock Option (Right to Buy)
2024-02-13 Jimenez Freddy A. Sell 20 000 Incentive Stock Option (Right to Buy)
2024-01-02 Martin Samuel Bates Buy 10 750 Common Stock
INSIDER POWER
75.37
Last 97 transactions
Buy: 2 900 849 | Sell: 507 801

Volumen Correlación

Largo: -0.12 (neutral)
Corto: 0.42 (neutral)
Signal:(43.552) Neutral

Celldex Therapeutics Inc Correlación

10 Correlaciones Más Positivas
NSTS0.918
BOKF0.917
FNWD0.917
GCBC0.916
NECB0.913
UMBF0.913
MSBI0.91
HMNF0.909
AHPI0.907
FSBC0.906
10 Correlaciones Más Negativas
CHMA-0.906
VTIP-0.906
DSPG-0.895
SUMO-0.893
SOPH-0.887
SMED-0.882
OSMT-0.878
NVCN-0.876
MNTV-0.876
DVCR-0.872

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Celldex Therapeutics Inc Correlación - Moneda/Commodity

The country flag 0.17
( neutral )
The country flag 0.17
( neutral )
The country flag 0.00
( neutral )
The country flag -0.12
( neutral )
The country flag 0.69
( moderate )
The country flag 0.26
( neutral )

Celldex Therapeutics Inc Finanzas

Annual 2023
Ingresos: $6.88M
Beneficio Bruto: $3.88M (56.30 %)
EPS: $-2.92
FY 2023
Ingresos: $6.88M
Beneficio Bruto: $3.88M (56.30 %)
EPS: $-2.92
FY 2022
Ingresos: $2.36M
Beneficio Bruto: $957 000 (40.60 %)
EPS: $-2.62
FY 2021
Ingresos: $4.65M
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-1.640

Financial Reports:

No articles found.

Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico